These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17676187)

  • 21. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
    Inderjeeth CA; Foo AC; Lai MM; Glendenning P
    Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strontium ranelate: a novel treatment in postmenopausal osteoporosis.
    Tournis S; Economopoulos D; Lyritis GP
    Ann N Y Acad Sci; 2006 Dec; 1092():403-7. PubMed ID: 17308165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generalized cutaneous drug eruption due to strontium ranelate.
    Boada A; Carrascosa JM; Leal L; Ferrándiz C
    J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):321-2. PubMed ID: 18624862
    [No Abstract]   [Full Text] [Related]  

  • 24. Interstitial granulomatous reaction to strontium ranelate.
    Groves C; McMenamin ME; Casey M; Barnes L
    Arch Dermatol; 2008 Feb; 144(2):268-9. PubMed ID: 18283194
    [No Abstract]   [Full Text] [Related]  

  • 25. [Strontium ranelate: new therapeutic agent for postmenopausal osteoporosis].
    Meunier PJ
    Med Sci (Paris); 2004; 20(6-7):631-3. PubMed ID: 15329809
    [No Abstract]   [Full Text] [Related]  

  • 26. Strontium ranelate: a physiological approach for optimizing bone formation and resorption.
    Marie PJ
    Bone; 2006 Feb; 38(2 Suppl 1):S10-4. PubMed ID: 16439191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Strontium ranelate: new perspectives for the management of osteoporosis.
    Cortet B
    Rheumatology (Oxford); 2009 Oct; 48 Suppl 4():iv1-2. PubMed ID: 19783588
    [No Abstract]   [Full Text] [Related]  

  • 28. Strontium ranelate (Fujisawa/Servier).
    Jupsin I; Collette J; Henrotin Y; Bruyere O; Sarlet N; Reginster JY
    Curr Opin Investig Drugs; 2005 Apr; 6(4):435-44. PubMed ID: 15898351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The new frontier of bone formation: a breakthrough in postmenopausal osteoporosis?
    Ruiz C; Abril N; Tarín JJ; García-Pérez MA; Cano A
    Climacteric; 2009 Aug; 12(4):286-300. PubMed ID: 19415543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Strontium ranelate and non-vertebral fracture in postmenopausal osteoporosis].
    Callejas Rubio JL; López Pérez L; Sánchez Cano D; Ortego Centeno N
    Med Clin (Barc); 2006 Jul; 127(7):279. PubMed ID: 16942738
    [No Abstract]   [Full Text] [Related]  

  • 31. Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.
    Brandi ML
    Curr Med Res Opin; 2010 Nov; 26(11):2553-63. PubMed ID: 20858031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women.
    Alexandersen P; Karsdal MA; Qvist P; Reginster JY; Christiansen C
    Bone; 2007 Jan; 40(1):218-22. PubMed ID: 17010685
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic agents for disorders of bone and calcium metabolism. Osteoporotic fracture prevention by strontium ranelate].
    Nakamura T
    Clin Calcium; 2007 Jan; 17(1):80-7. PubMed ID: 17211097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of strontium ranelate on spinal osteoarthritis progression.
    Bruyere O; Delferriere D; Roux C; Wark JD; Spector T; Devogelaer JP; Brixen K; Adami S; Fechtenbaum J; Kolta S; Reginster JY
    Ann Rheum Dis; 2008 Mar; 67(3):335-9. PubMed ID: 17965119
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
    Trémollieres F; Pouilles JM; Ribot C
    Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of strontium ranelate on serum insulin like growth factor-1 and leptin levels in osteoporotic post-menopausal women: a prospective study.
    Gulhan I; Bilgili S; Gunaydin R; Gulhan S; Posaci C
    Arch Gynecol Obstet; 2008 Nov; 278(5):437-41. PubMed ID: 18322691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of strontium ranelate for the mineralization of bone in postmenopausal women].
    Basurto L; Zárate A; Córdova N; Saucedo R; Galván R; Campos S; Hernández M
    Ginecol Obstet Mex; 2009 May; 77(5):227-30. PubMed ID: 19496517
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis.
    Halil M; Cankurtaran M; Yavuz BB; Ulger Z; Piskinpasa S; Gedik A; Haznedaroglu IC; Kirazli S; Ariogul S
    Ann Pharmacother; 2007 Jan; 41(1):41-5. PubMed ID: 17179188
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guidelines for the management of postmenopausal osteoporosis for GPs.
    O'Neill S; MacLennan A; Bass S; Diamond T; Ebeling P; Findlay D; Flicker L; Markwell A; Nowson C; Pocock N; Sambrook P; Singh MF;
    Aust Fam Physician; 2004 Nov; 33(11):910-9. PubMed ID: 15584331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Ballaouri I; Efstathiadou Z; Kita M; Avramidis A
    Clin Endocrinol (Oxf); 2009 Apr; 70(4):522-6. PubMed ID: 18625000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.